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Abstract
Recent studies have highlighted the overexpression of mucin 1 (MUC1) in various epithelial
carcinomas and its role in tumorigenesis. These mucins present a novel targeting opportu-
nity for nanoparticle-mediated photothermal cancer treatments due to their unique antenna-
like extracellular extension. In this study, MUC1 antibodies and albumin were immobilized
onto the surface of gold nanorods using a “primer” of polydopamine (PD), a molecular
mimic of catechol- and amine-rich mussel adhesive proteins. PD forms an adhesive plat-
form for the deposition of albumin and MUC1 antibodies, achieving a surface that is stable,
bioinert and biofunctional. Two-photon luminescence confocal and darkfield scattering
imaging revealed targeting of MUC1-BSA-PD-NRs to MUC1+ MCF-7 breast cancer and
SCC-15 squamous cell carcinoma cells lines. Treated cells were exposed to a laser encom-
passing the near-infrared AuNR longitudinal surface plasmon and assessed for photother-
mal ablation. MUC1-BSA-PD-NRs substantially decreased cell viability in photoirradiated
MCF-7 cell lines vs. MUC1- MDA-MB-231 breast cancer cells (p < 0.005). Agents exhibited
no cytotoxicity in the absence of photothermal treatment. The facile nature of the coating
method, combined with targeting and photoablation efficacy, are attractive features of these
candidate cancer nanotherapeutics.
Introduction
Au nanorods (AuNRs) are highly attractive constructs for tumor therapy due to their ease of
synthesis, tunable near-infrared (NIR) localized surface plasmon resonance (LSPR), and large,
functionalizable surface areas [1, 2]. The LSPR enhances optical properties, giving rise to high
absorbance, scattering, and two-photon luminescence phenomena that can be exploited for
photothermal cancer therapy and diagnostic imaging [1, 2, 3]. Patients with poor tumor mar-
gins or microscopic disease may be poor candidates for invasive surgical procedures and stand
to benefit from improved multimodal approaches [1]. The non-invasive penetration of NIR
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energy to AuNR-treated tissues permits localized hyperthermia resulting in tumor ablation. As
an added benefit, this heating may enhance tissue perfusion, increasing subsequent nanoparti-
cle loading and the efficacy of adjuvant chemotherapy or radiation [4, 5].
A primary challenge in AuNR-based therapies relates to modifying or replacing the initial
CTAB bilayer with a surface coating that is both bioinert and biofunctional [6]. A variety of
passivation strategies have been developed to overcome this problem. These strategies include
modification with amphiphillic synthetic polymers such as poly(ethylene glycol)-thiols
(PEG-SH)[7], lipids [8], electrostatic layers of polyanionic and polycationic polymers [9], and
most recently, proteins [10, 11]. The observed development of a protein corona following
nanoparticle contact in serum-containing biological media has supported interest in albumin
as a potential nanoparticle passivation agent [11].
Transmembrane mucins rich in glycosylated proline, threonine, and serine domains span
the epithelial cell membrane and provide a barrier function through ectodomains that project
over 100 nm from the cell surface [12]. Autoproteolysis generates C-terminal (MUC1-C) and
N-terminal (MUC1-N) subunits, the latter of which is anchored to the cell surface through a
stable but non-covalent complex with MUC1-C. While mucins are typically expressed at the
apical surface of cells to protect against environmental toxins, chronic stress induces a loss in
cell polarity leading to interactions of mucins with basolateral surface signaling molecules such
as receptor tyrosine kinases, triggering the downstream activation of proliferation and survival
genes. MUC1 is upregulated in response to the influx of inflammatory cytokines during inflam-
mation and infection, leading to loss of polarity and strengthening the protective function of
the mucosal barrier.
Although transient MUC1 activity functions to reduce inflammation, long-term overexpres-
sion promotes aggressive phenotypes in human cancers. MUC1-N contains heavily glyco-
slyated tandem repeats of 20 amino acids and is aberrantly underglycosylated in epithelial
carcinomas, exposing residues implicated in the immunosurveillance of cancer [13]. MUC1-N
is capable of blocking surface interactions and can also undergo secretion from the cell mem-
brane, permitting the receptor-like activation of MUC1-C in a variety of tumor signaling path-
ways [12]. The significance of MUC1 as a relevant therapeutic target is highlighted by its
atypical expression in> 64% of carcinomas diagnosed annually, and in over 90% of breast car-
cinomas irrespective of hormone or growth factor receptor status [14].
The function and exploitation of MUC1 as a tumor antigen continues to be elucidated [15].
Despite its antenna-like physical manifestation that in principle lends well to therapeutic tar-
geting of mucin-expressing tumors [12, 16], MUC1 has been underexploited in targeted cancer
therapy [17, 18, 19, 20]. Studies have demonstrated that MUC1 overexpression directly pro-
motes in vivo transformation of the mammary gland and its aberrant expression in trans-
formed cells can induce steric blocking or activation of cell surface receptors, serving as a
driving force for invasion [21] and chemotherapy resistance [22, 23]. Clinically, detection of
circulating serum mucin levels is an FDA-approved prognostic factor in the treatment of breast
cancer [12] and phase III clinical trials evaluating MUC1 based immunotherapies are under-
way [24].
Here, we demonstrate the polydopamine-mediated (PD) conjugation of gold nanorods
(AuNRs) with bovine serum albumin (BSA) and mucin 1 monoclonal antibodies (anti-MUC1)
for passivation and targeting, respectively (Fig 1). The major goals of this work were to identify
optimal conditions for nanoparticle functionalization and to demonstrate the feasibility of
photothermal ablation of MUC1 positive cancer cells via biofunctionalized AuNRs. The results
establish optimal conditions for surface modification of AuNRs with BSA and MUC1 antibody
and physiologic stability. Successful targeting and photoablation of MUC1 positive cancer cells
suggests these constructs may be useful anticancer therapeutics in the future.
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Materials and Methods
Materials
Dopamine hydrochloride, cetyltrimethylammonium bromide (CTAB, 99%), sodium tetra-
chloroaurate (III) dihydrate (NaAuCl4  2H2O, 99%), sodium borohydride (NaBH4, 98%),
ascorbic acid, glycine, and silver nitrate (AgNO3, 99%) were utilized for AuNR synthesis. The
pH value of the glycine solution (0.2 M) was adjusted to 8.0 with 2 M sodium hydroxide before
use. All reagents were obtained from Sigma-Aldrich (St. Louis, MO) unless otherwise noted.
AlexaFluor 633 goat anti-mouse immunoglobulin (IgG) was purchased from Invitrogen
(Carlsbad, CA). Anti-MUC1-N (VU4H5), anti-MUC1-N-PE (VU4H5 PE), mouse anti-
MUC1-C (H-6), goat anti-mouse-HRP IgG, goat anti-rabbit-HRP IgG, and rabbit anti-BSA
(B-140) primary antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA).
Goat anti-mouse IgG and goat anti-rabbit IgG antibodies conjugated to PE and/or HRP were
purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Ultrapure, deionized water
(18.2MO  cm) was used to prepare all aqueous solutions. SCC15, MCF-7 and MDA-MB-231
cancer cell lines were generous gifts from the laboratories of Dr. David Crowe at the University
of Illinois—Chicago and Dr. Dean Ho at Northwestern University.
Methods
Synthesis of gold NRs. The synthesis of CTAB-coated AuNRs (CTAB-NRs) is well estab-
lished in the literature and was performed according to a slightly modified method utilized by
Huang and coworkers [2]. All reagents were procured from Sigma Aldrich (St. Louis, MO)
unless otherwise noted. A 0.2 M CTAB aqueous solution (5.0 mL) was heated to 30°C and
mixed with 0.5 mM NaAuCl4 (5.0 mL). Ice-cold 0.01 M NaBH4 (0.6 mL) was added to this
mixture and sonicated for 5 minutes until a yellow-brown seed solution developed. Next,
50.0 mL of 0.2 M CTAB was gently mixed with 50.0 mL 1.0 mM NaAuCl4 and 0.1 mL 0.1 M
AgNO3 to form a growth solution. Ascorbic acid (78.8 mM, 0.7 mL) was added to the growth
solution as a mild reductant, followed by addition of 120 μL of the seed solution. After 45 min-
utes, 100 mL of this AuNR solution was mixed with 100 mL 0.2 M glycine (pH 8.0). This solu-
tion was allowed to react overnight without stirring at ambient temperature.
Biofunctionalization of gold NRs. For the synthesis of BSA-PD-NRs, 1 mL aliquots of
CTAB-NRs were centrifuged at 10,360 x g for 10 min to form a pellet. The supernatant was
Fig 1. Schematic illustration of MUC1 antibody-conjugated gold NRs (anti-MUC1-BSA-PD-NRs) with a polydopamine adlayer and BSA coating.
MUC1 antibodies serve as novel targeting constructs in the application of plasmonic photothermal therapy (A). Probing MUC1 targeting at underglycosylated
N- and C-terminal domains in various epithelial carcinomas will expand our cancer-targeting repertoire with the potential for synergistic therapeutic effects (B,
adapted from [12]).
doi:10.1371/journal.pone.0128756.g001
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discarded and the pellet was redispersed in 1.0 mL 10 mM bicine buffer (pH 8.5) supplemented
with 0.1 mg/mL dopamine hydrochloride. A polydopamine coating was developed with sonica-
tion at 37°C for 30 minutes. A 1.0 mL solution of 20 mg/mL BSA prepared in PBS (Ca2+ and
Mg2+ free) was added to this PD-NR mixture and allowed to react for another 30 minutes with
sonication. Following overnight reaction with gentle agitation, samples were centrifuged, redis-
persed in water or PBS, and stored at room temperature until further use. For antibody conju-
gations, 0.25–5.0 μg antibody was either reacted directly with CTAB- or PD-NRs prior to BSA
addition or premixed with BSA or buffer solutions prior to addition.
Antibody binding and quantification. Enzyme-linked immunosorbent assay (ELISA):
Goat anti-mouse IgG coated 96-well ELISA microplates (Pierce Biotechnology, Rockford, IL)
were rinsed with PBS + 0.05% Tween-20 (PBST). Mouse anti-MUC1-N/C antibody standards
and AuNR supernatant samples containing unknown quantities of MUC1-N or -C (100 μL/
well) were loaded and allowed to capture for 1 hr at room temperature with gentle mixing.
Plates were washed 3X in 200 μL PBST. Secondary goat anti-mouse IgG-HRP (Santa Cruz Bio-
technology, 100 uL/well, 1:6000 dilution) was incubated for 1 hour at 37°C with mixing.
The plate was washed 3X with PBST and a 1 mg/mL 2,2'-azino-bis(3-ethylbenz-thiazoline-
6-sulfuric acid) (ABTS) solution was prepared in 50 mM citric acid and 100 mM dibasic
sodium phosphate. Immediately prior to use, the ABTS solution was mixed with 10 μL 30%
H2O2 and added to wells (100 μL). ABTS color development based on the presence of HRP-
tagged secondary antibody was measured at 405 nm within 15 minutes on a Synergy H4
Hybrid Multi-Mode Microplate Reader (BioTek, Winooski, VT). The quantity of AuNR-
bound MUC1-N and MUC1-C antibodies was determined by subtracting the concentrations
detected in the sample supernatants from the known loading conditions during preparation.
Concentrations were calculated from point-to-point linear regression standard curves.
Optical spectroscopy. UV-Vis-NIR spectrophotometry: UV-Vis-NIR spectra of variously
modified AuNRs were recorded in a Hitachi U-2010 spectrophotometer (Hitachi City, Japan).
Longitudinal LSPR peak positions were determined and used as an indicator of surface modifi-
cation and aggregation.
Circular dichroism: Circular dichroism (CD) spectra were recorded with a J-815 CD Spec-
trophotometer (Jasco, Easton, MD) in the far-UV range (190–300 nm, 1 nm resolution) in 1
mm pathlength quartz cuvettes at ambient temperature. AuNR pellets (30 μL) were diluted in
900 μL ultrapure water for all measurements. BSA (0.25 mg/mL) served as a protein reference
while ultrapure water was used for background subtraction. The spatial arrangement and back-
bone conformation of protein amides gives rise to the characteristic CD spectra of specific sec-
ondary structures. Minima at 222 and 208 nm result from α-helical protein amides and light
polarized in the direction of α-helices, respectively [25]. While methods for the calculation of
% helicity are widely available [26], they require protein concentrations that could not be pre-
cisely determined in our experiments due to catecholamine interference [27]. Thus, to quantify




can be used as a coarse but convenient estimate of α-helical content, where θ represents the
raw ellipticity in millidegrees at 208 and 222 nm, respectively. Ratios between 0.80 and 0.95
represent single chain α-helices and increase with increasing α-helical content [26].
Cell culture. MCF-7 breast cancer cells were grown in high glucose DMEM (Invitrogen,
Carlsbad, CA) supplemented with 10% FBS (Invitrogen), 1% gentamicin sulfate (Invitrogen),
and 10 μg/mL recombinant human insulin (Santa Cruz Biotechnology). MDA-MB-231 cells
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were cultivated in RPMI 1640 (Invitrogen) with 10% FBS and 1% gentamicin sulfate. SCC15
oral squamous cell carcinoma was grown in high glucose DMEM supplemented with 10% FBS
and 1% gentamicin sulfate. All cell lines were grown at 37°C in humidified incubators with 5%
CO2.
Cell imaging. For fluorescence and two-photon luminescence (TPL) confocal imaging,
suspensions of cells (1x105) in 0.2 mL media were seeded into each of the 8 wells of a Lab-Tek
chambered coverglass slide (Nunc, Rochester, NY). Cells were grown to confluence and incu-
bated with fresh media containing AuNRs (3 pM). Cells were incubated with AuNRs for 24
hours, rinsed twice with PBS, and imaged live for TPL emissions in fresh media. Confocal
images were acquired with an inverted Axio Observer. Z1 microscope equipped with a 20X
objective lens and heated stage (37°C) set for 5% CO2 incubation (Zeiss, Oberkochen, Ger-
many). For TPL imaging, AuNRs were excited by a Mai Tai femtosecond (fs) Ti:Sapphire laser
(Mai Tai, Spectra-Physics, Santa Clara, CA) with a pulse rate of 130 fs and a repetition rate of
80 MHz. The TPL excitation wavelength was adjusted to the LSPR peak of the AuNR sample
(780 nm). An internal spectral detector adjusted for emissions between 500–615 nm detected
the TPL from AuNRs. A 543 nm HeNe laser was used for brightfield imaging. In darkfield
(DF) scattering experiments, cells were seeded (1x104 cells/well) on 16 well chamber slides
(Lab-Tek, Nunc), grown to confluence, and treated with 3.75 pM AuNRs in media for 1 hour.
Individual wells were rinsed 3X with PBS. The wells and chamber gaskets were carefully
removed and the slide was coverslipped for immediate imaging at 40X magnification with an
upright Leica DM2500 (Wetzlar, Germany) darkfield microscope. Images were acquired at a
constant exposure (f-stop 1/15) via an EOS Rebel T2i camera.
Electron microscopy. Electron microscopy (EM) grids (Ted Pella) were loaded with pel-
leted AuNRs (5 μl, 1 nM), counterstained with phosphotungstinic acid, and dried overnight at
ambient conditions. Grids were imaged with a Hitachi HD-2300 Ultra High Resolution field-
emission scanning transmission electron microscope (FE-STEM) (Hitachi City, Japan) in
transmission EM (TEM) and secondary electron (SE) modes.
z-Potential analysis. Modified and unmodified AuNRs (15 pM) were injected into stan-
dard folded capillary cells for z-potential measurements. Measurements were performed on a
Zetasizer Nano (Malvern Instruments, Worcestershire, United Kingdom) at ambient tempera-
ture and calculated as the mean of seven scans.
Photothermal therapy with MUC1-modified AuNRs. MCF-7, MDA-MB-231, and
SCC15 (5.0 x 105) cancer cells were cultured in 12 well TCP plates and grown to confluence
over 2–3 days. Wells were washed with PBS and treated with 0–3 pM anti-MUC1-N, anti-
MUC1-C, or BSA-only-modified AuNRs diluted in cell culture media. Following 1 h incuba-
tion at 37°C and 5% CO2, wells were rinsed 3X with PBS to remove unbound AuNRs and
marked at two focal points with equivalent confluence levels. One of each of these points was
exposed to a SuperK Versa broadband laser source (NKT Photonics, 480–850 nm, 1 mm spot)
for 3.5 min at a power density of 0.18 W/nm at the plasmon center wavelength (780 nm). After
a 24 hr incubation, cells were rinsed with PBS, and stained with calcein AM (2 uM) and propi-
dium iodide (4 uM) for live/dead imaging. Fluorescence microscopy was performed with a
Leica DMIRB microscope (Wetzlar, Germany) equipped with a 250 W Hg arc lamp and a
QIClick camera (QImaging, Surrey, BC Canada). Points of irradiation and non-irradiation
were captured in each well for comparison. Images were processed with the GNU Image
Manipulation Program (GIMP, v. 2.8.0). ImageJ was used to convert live/dead images into
black (background) and white (cells) thresholded masks. The area percentage of background
pixels with (Area %+NIR) or without laser exposure (Area %-NIR) was calculated with the
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Measure function in ImageJ. The following equation was used to quantify treatment efficacy:
% Viable Area ¼ 100 Area %þNIR
100 Area %NIR
 100 ð2Þ
Results were normalized to untreated wells ± NIR exposure. Experiments were repeated with
SCC15 oral and MDA-MB-231 breast cancer cell lines.
Statistical analysis. Student’s t-test was used to analyze percent antibody loading via
ELISA. Two-way analysis of variance (ANOVA) with Bonferroni post-tests was used to deter-
mine whether the mean % viable areas among MUC1+ and MUC1- cell lines were significant
with respect to dosing and treatment conditions. The differences were considered statistically
significant when the P value was< 0.05 (n = 3–6). All analyses were carried out by GraphPad
Prism version 5.0a for Mac (GraphPad Software, La Jolla, CA).
Results and Discussion
Albumin as a surface passivating agent
Minimal nonspecific fouling of surfaces is often a desirable goal in biomedical research and
medical device design [28, 29], for which the grafting of biomolecules and synthetic polymers
to a surface has been proposed as a solution [30, 31]. The degree and nature of nonspecific pro-
tein adsorption to a surface is dependent upon many factors including protein composition
(size, concentration, charge, and internal stability), environmental conditions (pH, tempera-
ture, and ionic strength), and surface properties (morphology, charge, and free energy) [32].
The use of adsorbed BSA as an approach to surface passivation has long been an intriguing
strategy for biomedical researchers. One of the earliest uses of this strategy was the observation
by Packham and others that platelets resist adsorption to albumin-coated glass tubes [33]. Pas-
sivation with albumin was proposed for plasmapheresis circuits, arterial prosthetics, and other
blood-contacting devices to prevent thrombogenesis, however this approach showed limited
efficacy due to low surface coverage or displacement of physisorbed albumin by proteins with
higher binding affinities [34].
Subsequent attempts were made to cross-link adsorbed albumins with glutaraldehyde or
gamma irradiation treatments; however, the resultant loss in protein flexibility limits their abil-
ity to contribute to steric repulsion [35]. Since these first observations, albumin has been used
to modify iron oxide [36], polystyrene [37], Ag and Au [38, 39], quantum dot [40], and lipo-
somal nanoparticles [41]. Studies have not only demonstrated that BSA-conjugated nanoparti-
cles reduce aggregate formation, but they have also revealed enhancement of quantum yield,
which is of relevance to the photothermal applications explored in this study [42].
Polydopamine for functionalizing nanoparticles with biomolecules
In this study we describe a mussel adhesive protein inspired strategy for anchoring BSA and
antibody onto the surface of gold nanorods. The marine mussel’s promiscuous fouling of
organic and inorganic surfaces has been attributed by Waite and others to the unusual proteins
found in the terminal adhesive plaques of its byssal threads [43, 44]. Specifically, high levels of
the catechol-containing amino acid 3-4-dihydroxyphenylalanine (DOPA) and the amine-con-
taining amino acid lysine occur in byssal plaques, and this observation has greatly influenced
the design of versatile molecular adhesives, anchors for synthetic polymers, and general strate-
gies for surface coatings [44, 45].
Motivated by the high catecholamine content of mussel adhesive proteins, dopamine was
identified as a simple structural mimic of the mussel foot protein 5 (Mfp-5) and shown to
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spontaneously deposit thin melanin-like films on virtually any bulk material surface [46]. Poly-
dopamine (PD) films are formed through the spontaneous polymerization of dopamine mole-
cules under mildly alkaline aqueous conditions that mimic the marine environment. Although
the mechanism of formation and final composition of PD are still under investigation [47, 48,
49, 50, 51, 52], under the conditions normally used to form PD coatings dopamine is oxidized
to yield dopamine-quinone which subsequent to intramolecular rearrangement, further oxida-
tion and intermolecular coupling, yields a eumelanin-like heterogeneous polymer [44]. It is
likely that a variety of structural subunits and bonding types are found within the PD film as
well as at the PD-substrate and PD-protein interfaces, including covalent bonds, electrostatic
and strong noncovalent interactions such as charge transfer, hydrogen bonding, and π-
stacking. The adhesive and reactive nature of polydopamine thin films was exploited as a con-
venient platform or ‘primer’ onto which can be deposited additional secondary coatings via a
variety of potential mechanisms, including covalent linkage with organic thiol, amine, and his-
tidine residues [53]. With this two-step approach a wide variety of functional applications of
polydopamine have been developed for biomedical applications [54], such as the grafting
of PEG-thiols to suppress biofouling [46, 55] or the specific promotion of cell adhesion to sur-
faces [46].
Preparation and characterization of BSA modified AuNRs
Modification of AuNRs with PD was performed as described previously [56, 57], yielding
AuNRs surrounded by a thin PD coating. The presence of PD was confirmed by UV-vis red
shift (Fig A in S1 File). PD-NRs were found to aggregate in buffer, but redispersion in BSA
solution and isolation by centrifugation led to stable dispersions of BSA-PD-NRs. Using the
solution AuNR LSPR intensity and peak shift (Fig B in S1 File) analyzed via UV-Vis-NIR spec-
trophotometry as a measure of NR stability, screening of a range of BSA concentrations (0–30
mg/mL) used in the two-step coating method led to the identification of an optimal protocol
consisting of 0.1 mg/mL dopamine for PD coating of CTAB-NRs followed by stabilization in
10 mg/ml BSA. Under these optimal conditions, aggregation of BSA-PD-NRs was seven-fold
less compared to PD-NRs (Fig B in S1 File). All subsequent experiments were performed on
PD-NRs modified at 20 mg/mL BSA in order to ensure full passivation of the PD underlayer
that may otherwise serve to promote AuNR aggregation. AuNRs (20 x 60 nm) modified with
PD and BSA (20 mg/mL) were imaged via TEM following counterstaining with phosphotungs-
tic acid to provide contrast for the organic BSA layer. A layer measuring ~15 nm in thickness
was visualized on well-separated BSA-PD-NRs in SE mode (Fig 2A). The attenuation of XPS
Au4f signal of a gold surface observed upon exposure to dopamine and BSA is consistent with
the deposition of a PD coating followed by grafting of BSA (Fig C in S1 File).
AuNRs were further evaluated via UV-Vis-NIR spectroscopy to analyze changes in the lon-
gitudinal LSPR peak position (Fig B in S1 File). BSA-DP-NRs demonstrated a plasmon red
shift of 10 nm due to changes in the local dielectric environment resulting from the surface
adsorption events. This change in the LSPR wavelength maximum, Δλmax, corresponds to an
adsorbed thickness d of 15 nm based on equation [57, 58],







Wherem is the bulk refractive index response of the nanoparticle, Δn is the refractive index
change induced by the adsorbing species, and ld is the decay length of the electromagnetic field.
This calculated thickness is in agreement with our TEM observations (Fig 2A). Additionally, z-
potential measurements were recorded to track AuNR biofunctionalization and are reported in
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Table 1. The stepwise change in z-potential with PD and BSA modification culminated in a
negatively-charged BSA coating.
BSA binding to PD-NRs most likely occurred via the noncovalent mechanisms described
above or by covalent coupling to any of 60 available surface lysine residues [38]. Parallel experi-
ments conducted on untreated CTAB-NRs dispersed in 10 mg/ml BSA did not yield a stable
suspension, indicating the importance of PD in enhancing BSA passivation. Although higher
concentrations of BSA were found to stabilize CTAB-AuNRs in the absence of PD as indicated
by sedimentation experiments (Fig B in S1 File) and ELISA (data not shown), these constructs
failed to facilitate optimal antibody immobilization in later experiments.
The tertiary structure of serum albumin is composed of three domains (I-III), which are fur-
ther organized into nine loops by 17 disulfide linkages [59]. Notably, BSA maintains a single
free sulfhydryl residue at Cys-34, whose presence is implicated in both metal chelation and free
radical scavenging activity [60]. In physiological conditions, BSA maintains 67% α-helical con-
tent, 10% β-turns, and 23% extended chains [59, 61]. At physiologic pH BSA maintains a net
negative charge (pI = 4.7), contributing to its excellent water solubility, although a decrease in
effective charge is expected as a function of increasing solution pH [59, 62], elucidating the
potential importance of electrostatic interactions on albumin binding to CTAB or polydopa-
mine modified surfaces. Importantly, the electrostatically driven adsorption of negatively
charged BSA at pH 8.5 to AuNR surfaces decorated by cationic CTAB ammonium head groups
Fig 2. Bovine serum albumin (BSA) coating on polydopamine-primed gold NRs. (A) Electron microscopy of BSA-PD-NRs in secondary electron mode.
Scale bar = 600 nm; Inset = 50 nm; (B) Circular dichroism of modified vs. unmodified gold NRs. BSA-modified NRs were modified with 10 or 20 mg/mL BSA,
as indicated. The concentration of the BSA control was 0.25 mg/mL. Protein denaturation into β-sheet formation is indicated on PD-treated NRs modified with
a sub-optimal concentration of BSA. Otherwise, BSA secondary structure is preserved, as quantified by the respective α-helical propensity of each
modification.
doi:10.1371/journal.pone.0128756.g002
Table 1. AuNR zeta-potential measurements.
Sample ζ-potential (mV)
CTAB-NR 20.0 ± 0.7
PD-NR 2.6 ± 0.6
BSA-NR -21.7 ± 1.3
BSA-PD-NR -30.3 ± 0.6
IgG-BSA-PD-NR* -14.9 ±1.2
Decreasing zeta-potential measurements verify successive surface modifications.
*IgG—AlexaFluor 633 goat anti-mouse immunoglobulin.
doi:10.1371/journal.pone.0128756.t001
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was found to induce some denaturation of α-helical secondary structure as observed via CD
(Fig 2B).
We proposed polydopamine-mediated adsorption of BSA as a simple strategy to improve
the colloidal stability of gold nanorod suspensions while minimizing impact to the secondary
structure of the protein coating. We found that BSA-PD-NRs were capable of maintaining
a higher α-helical propensity (p(α) = 0.899) compared to BSA-only modified counterparts
(p(α) = 0.824), and that this ratio more closely approached the control BSA standard (0.25 mg/
mL, p(α) = 0.917). The high alpha-helical propensity is considered advantageous, as denatur-
ation may lead to the undesired exposure of immunostimulatory domains in BSA [42, 63]. Fur-
thermore, an electrostatically driven modification as would be the case in the absence of
PD, may be unstable in physiological environments [11], permitting the displacement of pas-
sivating BSA by higher affinity proteins that can drive the elimination of nanoparticles via the
reticuloendothelial system [64]. Partial BSA denaturation may reveal and perturb interior
disulfide bonds, which have been shown to contribute to bonding through Au-thiol interac-
tions [65].
Strikingly, BSA-PD-NRs prepared at sub-optimal 10 mg/mL BSA concentrations aggregated
as denatured β-sheets (Fig 2B). Hydrogen bonding interactions can bring together antiparallel
peptide strands in neighboring BSA molecules, producing characteristic β-sheet CD spectra. At
low BSA concentrations, polydopamine may be contributing to intermolecular hydrogen
bonding, whereas an optimized excess of BSA may inhibit this bridging. In this case, incom-
plete BSA passivation may permit PD to contribute to the observed change in secondary struc-
ture. Furthermore, high surface coverage density is generally associated with the preservation
of protein native structure [66].
Physiological stability of functionalized AuNRs
To test the ability of modified AuNRs to resist aggregation in physiologically relevant environ-
ments, BSA-PD-NR, BSA-NR, PD-NR, and CTAB-NR samples were repeatedly centrifuged
and resuspended in DMEM cell culture media and UV-Vis-NIR spectra acquired (Fig D in S1
File). BSA-PD-NRs (20 mg/mL BSA, 0.1 mg/mL PD) demonstrated excellent longitudinal
LSPR peak intensity after 5 sedimentation challenges, whereas BSA-NR samples showed a 12%
greater loss. The LSPR peak of BSA-PD-NR blue shifted ~5 nm whereas BSA-NR decreased by
~7 nm, suggesting decreased surface stability in the absence of PD. PD-NRs showed evidence
of aggregation, as demonstrated by peak broadening and the absence of the longitudinal LSPR
peak after 5 cycles. Long-term stability was evaluated over the course of one month, with no
appreciable loss in LSPR intensity of BSA-PD-NRs (Fig D in S1 File), underscoring the physio-
logical stability of the modified AuNRs.
Antibody conjugation was qualitatively confirmed via SDS-PAGE (Fig E in S1 File) and
optical spectroscopy of LSPR red shift (Fig 3A). To quantify the degree of MUC1 antibody con-
jugation to modified AuNRs, a MUC1 ELISA was designed. Goat anti-mouse coated micro-
plates were used to capture unbound mouse anti-human MUC1 antibodies sourced from
AuNR sample supernatants to calculate the amount of depleted antibody from known starting
concentrations. The results of the ELISA indicate that antibody was completely incorporated in
BSA-PD-NR samples whereas BSA-NR modified with MUC1-N (BSA-NR N) incorporated
only 72% of the available antibody under the same conditions (p< 0.05)–affording a facile and
versatile coupling strategy for cancer targeting applications. Treatment of BSA-NR with
MUC1-C antibodies (BSA-NR C) resulted in the immediate aggregation of the sample (Fig
3B), further supporting the potential covalent nature of the BSA-PD coating and its robust abil-
ity to survive in physiologically relevant environments.
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Fig 3. Anti-MUC1 conjugation efficiency. (A) LSPR peak red shifting is observed with sequential BSA and anti-MUC1 modifications. (B) ELISA reveals
total incorporation of MUC1-N and—C antibodies was achieved (* p < 0.05) only in PD-primed NRs additionally stabilized via a BSA layer. Near 100%
loading in MUC1-C-BSA-NR samples has no practical significance as antibody addition induced complete NR aggregation (#). To quantify the differential
MUC1 expression profiles in our cell lines, cells were treated with PE-conjugated MUC1 antibodies and analyzed via flow cytometry for their mean
fluorescence intensities (MFI) against cells labeled with isotype controls. Both MCF-7 (MUC1++) and SCC15 (MUC1+) cells demonstrated an enhanced MFI
in agreement with literature reports [16, 67, 68]. As expected, MUC1-deficient MDA-MB-231 (MUC1-) cells did not show an appreciable increase in anti-
MUC1 PE labeling (Fig F in S1 File).
doi:10.1371/journal.pone.0128756.g003
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Cytotoxicity and imaging of modified AuNRs in cells
Because cationic CTAB-coated surfaces have been shown to display indiscriminate cytotoxicity
by binding to negatively-charged cell membranes [6, 69], we first investigated cytotoxicity of
our modified NRs as well as the CTAB-NRs they were prepared from. After modification with
PD and BSA, CTAB-mediated cytotoxicity of AuNRs was successfully eliminated (Fig G in S1
File) in accordance with the lack of a positive surface charge (Table 1).
Two-photon luminescence (TPL) imaging of MCF-7 breast cancer cells was pursued follow-
ing treatment with 3 pM AuNRs (Fig 4). No non-specific cell uptake was observed with
BSA-PD-NR, in contrast to BSA-NR. Additionally, enhanced cell colocalization was observed
with treatment of MUC1-N- and MUC1-C BSA-PD-NR conjugates. In contrast, imaging of
MUC1-deficient MDA-MB-231 breast cancer cells demonstrated no targeting of MUC1-
conjugated BSA-PD-NRs and some non-specific uptake of BSA-NRs. In addition to the excel-
lent analytical contrast afforded by TPL imaging, AuNRs are efficient scatterers of incident
light, a phenomenon that can be exploited for contrast imaging via darkfield microscopy. Both
MCF-7 and SCC15 cells demonstrate enhanced labeling with MUC1-modified BSA-PD-NRs
vs. unmodified BSA-PD-NRs (Fig 5). In contrast, some uptake of BSA-NRs was detected in all
cell lines regardless of MUC1 status, suggesting that the passivation of the NR surface in the
absence of PD is incomplete or is susceptible to displacement.
Fig 4. Two-photon luminescence imaging. Two-photon luminescence (TPL) confocal imaging of MCF-7 and MDA-MB-231 breast cancer cells 24 h post
treatment with NRs. Brightfield (BF, grayscale) and AuNR TPL images (red) reveal specific targeting in MUC1+ MCF-7 cells. Scale bar = 50 μm.
doi:10.1371/journal.pone.0128756.g004
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In vitro MUC1-BSA-PD-NR-mediated photothermal therapy
Patients with undefined tumor margins or advanced disease may be poor candidates for surgi-
cal resection and could benefit from improved multimodal nanotherapeutic approaches [1].
Upon mild heating, enhancement of tissue perfusion and reoxygenation has been shown to
synergistically increase the efficacy of chemotherapy and radiation. With the added conjuga-
tion of targeting ligands to a nanorod surface, researchers have demonstrated highly desirable
ablative specificity with minimal damage to healthy neighboring tissues [4, 5]. The non-inva-
sive penetration of NIR energy to AuNR-treated tissues permits localized tumor ablation via
hyperthermia as excited electrons convert adsorbed photon energy into heat [70]. NIR light
has been demonstrated to penetrate breast tissue to a depth of at least 10 cm, providing com-
pelling support for future clinical translation [71].
Photothermal therapy was evaluated in breast and oral cancer cell lines with varying levels
of carcinoma-associated MUC1 expression. MCF-7, MDA-MB-231, and SCC15 cells were
treated with 0, 0.75, 1.5, or 3 pM of variously modified AuNRs and subjected to NIR photo-
irradiation at a power density of 0.18 W/nm. Fluorescent live/dead staining of cells treated
with anti-MUC1-modified AuNRs demonstrated a dose-dependent enhancement of cellular
ablation that was MUC1 specific in MCF-7 and SCC15 cell lines (Fig 6). Thermal elevation
curves measured in aqueous suspensions of variously modified nanorods revealed heat
increases sufficient for therapeutic hyperthermia (Fig H in S1 File).
The overall impact on MCF-7 cells was most profound, in accordance with the high carci-
noma-associated MUC1 expression observed via flow cytometry. Treatment with MUC1-C-B-
SA-PD-NR followed similar trends. Because cell death was accompanied by delamination
under the conditions of our experiments (Fig I in S1 File), analysis of normalized viable cell
areas was used for quantification, revealing MUC1-dependent cell death in anti-MUC1
Fig 5. Darkfield imaging. AuNR uptake by cells detected by darkfield scattering imaging of MUC1-overexpressing SCC15 oral or MCF-7 breast cancer cells
following treatment with MUC1-modified NRs. Scale bar = 50 μm.
doi:10.1371/journal.pone.0128756.g005
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Fig 6. Photothermal therapy of breast and oral cancer cells. Photoablation of cells with NKT Photonics
SuperK Versa near-infrared (NIR) light source (480–850 nm). Cells were imaged with calcein AM (live, green)
and propidium iodide (dead, red) to visualize photoablation efficiency following treatment with increasing
doses of AuNRs. Due to the delamination of dead cells, no red staining is present in the treated regions of
interest. In the MCF-7 cell line, this dead staining was occasionally observed prior to delamination (Fig I in S1
File). Scale bar = 100 μm.
doi:10.1371/journal.pone.0128756.g006
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modified AuNRs vs. non-targeted BSA-PD-NRs in MCF-7 and SCC15 cell lines ( p< 0.001).
Two-way ANOVA indicates a statistically significant impact of dose (p< 0.0001) and treat-
ment (p< 0.0001). Photoablation was observed at lower doses in MCF-7 vs. SCC15 cells (Fig
G in S1 File), a result that is consistent with their differential MUC1 expression profiles (Fig F
in S1 File). MUC1-deficient MDA-MB-231 cell lines did not present any pattern of photoabla-
tion upon NIR exposure, nor was viability negatively impacted in non-photoirradiated control
samples (Fig 7).
Conclusions
In this study, we report a method for polydopamine-mediated coating of AuNRs with BSA for
passivation and straightforward conjugation of MUC1 antibodies for cancer cell targeting. The
modified AuNRs were stable in physiologically relevant culture media and selectively bound to
cells overexpressing MUC1. Illumination of treated cells with NIR light induced cell death in
MUC1 positive cancer cell lines. Taken together, these results demonstrate the viability of our
strategy for the surface modification of AuNRs for cancer cell targeting. Given the emerging
Fig 7. Quantification of breast and oral cancer photothermal therapy. Analysis of normalized viable
cell areas reveals MUC1-dependent therapy vs. non-targeted BSA-PD-NRs in MCF-7 and SCC15 cell lines
(* p < 0.05, ** p < 0.01, *** p < 0.001). Two-way ANOVA reveals a statistically significant impact of dose
(p < 0.0001) and treatment (p < 0.0001). The interaction of dose and treatment was found to be statistically
significant only for MCF-7 cells (p < 0.001).
doi:10.1371/journal.pone.0128756.g007
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body of literature implicating underglycosylated MUC1 in a large number of cancers, the
results establish the potential use of MUC1 antibody modified AuNRs for the targeting and
photoablation of MUC1-overexpressing epithelial malignancies.
Supporting Information
S1 File. Fig A) Stepwise modification of AuNR surfaces by polydopamine and BSA induces
a shift in the plasmon absorbance. Normalized LSPR spectra obtained via UV-vis-NIR spec-
troscopy indicate a red shift in peak position upon surface modification with PD (0.1 mg/mL)
and BSA (20 mg/mL). See also [57]. Fig B) Polydopamine enhances the stability of BSAmod-
ified NRs after five cycles of centrifugation and resuspension. Au-NRs were incubated in
BSA at the concentrations shown, subjected to five cycles of centrifugation and redispersion in
water and then analyzed for LSPR peak intensity and peak shift. (A) Normalized LSPR peak
intensities of PD-NRs treated with 0–30 mg/mL BSA ( p< 0.001). (B) LSPR shifts of
AuNRs with (+PD) and without (-PD) polydopamine treated with 0–30 mg/mL BSA. Gener-
ally, a high LSPR peak intensity and low LSPR shift is indicative of improved colloidal stability.
Although nanorods without PD were effectively passivated by BSA at high concentration, pas-
sivation was achieved at a lower BSA concentration in the presence of PD (p< 0.0001). Fig C)
Au4f XPS analysis of surface modification by PD and BSA [72]. CTAB-treated Au/Ti/Si
wafers were subjected to sham (bicine buffer), PD, BSA, and PD+BSA modifications as a
model of AuNR surface coating steps. High-resolution Au4f scans reveal decreasing Au sub-
strate intensities with successive modifications. Less substrate is detected with BSA-only modi-
fication compared to PD+BSA coatings, suggesting that PD promotes a thinner or more
uniform surface coverage. Fig D) Physiological stability of modified gold nanorods. AuNR
suspensions were measured by UV-Vis-NIR spectroscopy after sedimentation challenges, con-
sisting of five cycles of centrifugation and pellet redispersion in DMEM cell culture media (A)
and PBS (B). Stability of MUC1-modified BSA-PD-NRs was maintained over the course of one
month. CTAB-NR is not shown at day 30 due to the complete aggregation of the sample. Fig
E) Qualitative antibody immobilization. SDS-PAGE analysis of standards (BSA, ladder, and
AlexaFluor 633-IgG) and supernatants after modification of AuNRs (IgG-BSA-PD-NR,
IgG-BSA-NR) indicates that treatment of AuNR surfaces with PD captures more antibody
onto the AuNR as seen in the reduction in IgG band intensity of the supernatant for PD treated
AuNRs (lane 4) compared to BSA modified AuNR (lane 5). Fig F) MUC1 status of cell lines
analyzed by flow cytometry. Labeling with PE-MUC1-N antibody and IgG1a isotype control
antibody confirms differential MUC1-N expression in the experimental cell lines: MCF-7,
MUC1++; SCC15, MUC1+; MDA-MB-231, MUC1-. Fig G) Cytotoxicity of biofunctionalized
AuNRs. MDA-MB-231 and MCF-7 breast cancer cell lines were exposed to 3 pM CTAB-NR
(blue), BSA-NR (green), or BSA-PD-NR (orange) for 30 minutes and compared against unex-
posed control cells (red). Cells were stained with PI and analyzed via flow cytometry. CTAB-
mediated cytotoxicity was mitigated in all modification conditions. Fig H) Temperature eleva-
tion curves for NIR-exposed nanorod solutions. Aqueous solutions containing 3 pM BSA,
anti-MUC1-N, or anti-MUC1-C-modified PD-NRs demonstrated temperature elevations suf-
ficient for therapeutic hyperthermia [8], supporting the photothermal ablation observed in
experiments. These bulk heating profiles differ significantly from NIR-exposed water alone
(ΔT 2–3°C, see Fig 3A in [9]). Fig I) Live/dead staining of MCF7 cells in treated and con-
trol conditions. Photoablation of MCF7 cells (MUC1++) with NKT Photonics SuperK Versa
near-infrared (NIR) light source (650–850 nm) (+IR). Cells were imaged with calcein AM (live,
green) and propidium iodide (dead, red) to visualize photoablation efficiency following treat-
ment with increasing doses of modified AuNRs. In this experiment, the red staining of dead
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cells could be observed prior to cell delamination. Similar detachment or photothermolysis of
ablated cells has been reported in the literature [73, 74, 75, 76, 77]. Scale bar = 100 μm.
(ZIP)
S2 File. Supplemental methods detailing UV-vis-NIR, XPS, flow cytometry, SDS-PAGE,
temperature elevation, and photothermal experiments are provided.
(PDF)
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